30 May 2019
Bookmark and Share

WADA publishes Stakeholder Notice regarding meat contamination

On 16 May 2019, the World Anti-Doping Agency’s (WADA’s) Foundation Board decided to amend Article 7.4 of the World Anti-Doping Code (Code) to allow WADA-accredited Laboratories (Laboratories) to report Atypical Findings (ATFs) for the Prohibited Substance clenbuterol.

Under the current version of Article 7.4 of the Code, Laboratories may only report analytical testing results for exogenous Prohibited Substances as Adverse Analytical Findings (AAFs) but not as ATFs, which does not allow for investigations to take place when potential meat contamination scenarios arise – as has been the case with clenbuterol. As such, if the current Code is strictly followed, Anti-Doping Organizations (ADOs) are required to assert an Anti-Doping Rule Violation (ADRV) against the athlete if the B sample results confirm the A sample findings (or the athlete waives the analysis of their B sample).

The purpose of the amendment to Article 7.4 of the Code – which will come into force on 1 June 2019 and is an interim solution until the 2021 Code and the forthcoming International Standard for Results Management (ISRM) come into effect – is to provide ADOs with the possibility of conducting an investigation when low concentrations of identified Prohibited Substances that are known meat contaminants are detected by Laboratories and reported as ATFs. This will ensure that valid meat contamination cases are dealt with fairly and, notably, may prevent athletes from having their competition results disqualified as a result of eating contaminated meat.

In order to provide guidance to ADOs faced with potential meat contamination cases, WADA has developed a Stakeholder Notice regarding Meat Contamination (Notice) that details the reporting instructions for Laboratories depending on the concentration of clenbuterol detected in an athlete’s sample and includes the investigative steps that ADOs must follow in such situations.

After following the instructions and investigative steps indicated in the Notice, ADOs may close cases and allow an athlete to retain their results (for samples collected in-competition) if it is determined that the detection of clenbuterol in their sample is consistent with meat contamination. However, if, following the investigation, the reported ATF is not consistent with meat contamination, or if the concentration of clenbuterol exceeds the designated threshold, an ADRV will be asserted and the standard results management process will proceed.

WADA hopes that the instructions found in the Notice and that the amendment to Article 7.4 of the Code will assist ADOs faced with potential clenbuterol meat contamination cases and will ensure that cases are managed fairly for all athletes.

Please feel free to contact rm@wada-ama.org  should you have any questions or concerns.